Gilead Sciences, Inc

Write a Review973-605-8200

OPEN NOW - Closes at 5:00pm

Immunomedics strives to improve health care and extend life by focusing on the development and commercialization of humanized monoclonal antibody-based treatments for cancer, autoimmune and other serious diseases. The Food and Drug Administration recently fast tracked the company s leading drug candidate, Epratuzumab for the potential treatment of the world s estimated 3 million sufferers of lupus. Immunomedics is traded publicly on NASDAQ under the symbol IMMU and maintains corporate headquarters in Morris Plains, N.J.